To determine how consistently Chinese glioblastoma multiforme (GBM) patients were treated according to the Stupp regimen. The proportion of treatments conforming to the Stupp regimen and reasons for nonconformity were evaluated in 202 newly diagnosed GBM patients. Only 15.8% of GBM patients received treatments compliant with the Stupp regimen. The main deviations were temozolomide dosages >75 mg/m (58/120; 48.3%) and treatment durations <42 days (84/120; 70.0%) in the concomitant phase and temozolomide dosages <150 mg/m (89/101; 88.1%) in the maintenance phase. Median overall survival (27.09 vs 18.21 months) and progression-free survival (14.27 vs 12.10 months) were longer in patients who received Stupp regimen-compliant treatments. Increased conformity to the Stupp regimen is needed for GBM patients in China.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2021-0435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Silico and In Vitro Study of mRNA Biomarkers for Glioblastoma Multiforme Resistance to Temozolomide (TMZ): The Association with Stemness.
Asian Pac J Cancer Prev
December 2024
Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor that primarily affects adults. The Stupp Protocol, which includes surgical resection, chemoradiation, and monotherapy with temozolomide (TMZ), is the standard treatment regimen for GBM. However, repeated use of TMZ leads to resistance in GBM cells, resulting in a poor prognosis for patients.
View Article and Find Full Text PDFOptimizing glioblastoma treatment: A systematic review and meta-analysis of local injection and systemic drug delivery system in murine models.
Surg Neurol Int
November 2024
Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Background: Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis. The current gold standard for GBM treatment, known as the Stupp protocol, includes maximal safe surgical resection followed by radiotherapy and temozolomide chemotherapy. Despite extending survival modestly, this regimen is associated with significant side effects and limited efficacy, resulting in a median survival (MS) of 15 months and a 5-year survival rate of only 7%.
View Article and Find Full Text PDFUnraveling Glioblastoma: TME Implication and Gene Therapy Advances.
Curr Gene Ther
November 2024
Department of Biomedical Sciences, School of Biosciences & Technology, VIT, Vellore Dt. PIN:632014, India.
Glioblastoma is a malignant manifestation of a solid brain tumour with a very dismal prognosis due to an overall median survival of 14 months. The currently administered Standard treatment plan, the STUPP regimen, is not very effective in tackling this neoplasia. A major concern that affects the development of new drug formulations, specifically for Glioma, is the inherent sub-clonal heterogeneity, which includes the dynamic and intricate nature of the Tumour Microenvironment (TME).
View Article and Find Full Text PDFA patient with heterochronous double primary tumor of basal ganglia germ cell tumors followed by diffuse hemispheric glioma: a case report.
Childs Nerv Syst
December 2024
Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Article Synopsis
- Basal ganglia germ cell tumor (BGGCT) is a rare CNS tumor, while diffuse hemispheric gliomas (DHGs) are invasive tumors affecting the brain's hemispheres and require both histopathological and molecular pathology for diagnosis.
- A patient initially diagnosed with BGGCT responded well to chemoradiotherapy but later developed a high-grade glioma, confirmed as DHGs after surgery and genetic testing revealed a possible pathogenic variant in the FANCA gene.
- This is the first documented case of a patient having two distinct tumors, starting with BGGCT followed by DHGs, highlighting the complexity of tumor diagnosis and management over time.
Efficacy and Cognitive Outcomes of Gamma Knife Radiosurgery in Glioblastoma Management for Elderly Patients.
J Pers Med
October 2024
Department of Neurosurgery, Latino America Valerio Foundation, Weston, FL 33331, USA.
Background: Gamma Knife Radiosurgery (GKRS), a specific type of Stereotactic Radiosurgery (SRS), has developed as a significant modality in the treatment of glioblastoma, particularly in conjunction with standard chemotherapy. The goal of this study is to evaluate the efficacy of combining GKRS with surgical resection and chemotherapy in enhancing therapeutic effects for glioblastoma patients aged 55 years and older.
Methods: This prospective clinical study, conducted in accordance with the STROBE guidelines, involved 49 glioblastoma patients aged 55 years and older, treated between January 2013 and January 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!